- Scott Phillips
- Dec 26, 2015
- Anne DiSante, Julie Rojewski, Michigan State University, NIH, NIH BEST Program, Stephen Rapundalo, wayne state university
The SearchLite recently hosted a NIH BEST career panel discussion at Michigan State University. The panel discussion about career transition was held at the offices of MSU Technologies on Thursday, December 17th. The panel featured three speakers and focused on career opportunities in Life Sciences for PhD Candidates and Post Docs. Students from the http://romshedfarm.co.uk/wp-cron.php?doing_wp_cron=1514543613.8607339859008789062500 MSU BEST Program and http://allweatherfencing.com/?wordfence_logHuman=1 Wayne State University BEST Program participated in the career panel. BEST stands for buy Pregabalin uk next day delivery Broadening Experiences in Scientific Training. The National Institute of Health (NIH) has selected and funded 17 research sites in the US to participate in the BEST Program.
The panelists included Anne DiSante, Associate Director, MSU Technologies at Michigan State University; Stephen Rapundalo, President and CEO of MichBio and Julie Rojewski, Program Manager for MSU BEST. Anne, Stephen and Julie spoke about their personal career experiences from
many different aspects of the Life Sciences Field and offered advice to students who are considering transition out of academia and into industry. Much of the advice focused on professional networking and staying abreast of current topics in industry.
Another topic was job creation in Life Sciences including new startups. Michigan is home to the Michigan Life Sciences Corridor, a biotechnology initiative of the Michigan Economic Development Corporation (MEDC). The MLSC invests in biotech research at four Michigan institutions: the University of Michigan in Ann Arbor, Michigan State University in East Lansing, Wayne State University in Detroit, and the Van Andel Institute in Grand Rapids. The MEDC administers the program. A BioEnterprise Midwest Healthcare Venture report found that Michigan attracted $451.8 M in new biotechnology venture capital investments from 2005 to 2009.